Background: A strategy of emergency revascularization (ERV) in patients with cardiogenic shock (CS) complicating an acute myocardial infarction (MI) improves 12-month survival compared to initial medical stabilization with possible delayed revascularization (IMS). Due to the critical nature of CS patients pre-revascularization, it is unclear whether this survival benefit is associated with good or poor functional class and quality of life (QOL) Methods: Our study cohort (n=126) was patients with at least one phone interview at 2weeks post discharge (baseline), 6 and 12-months post-MI. Data were collected for a predefined secondary endpoint of the SHOCK trial using standardized instruments. Results: At 1-year post-MI 87% of survivors were in NYHA I/II. The QOL score and the distributions of NYHA functional class (FC) were similar in the 2 treatment assignments at all time points (p>0.1). The proportion of patients at 1-year with improvement in FC was similar in the 2 treatment groups (18% overall), in the IMS group fewer remained stable (44% vs.71%) and more deteriorated or died (34% vs.15%). Proportion of patients in NYHA I/II at 2-week (baseline) and 1-year was similar (67% and 71%), in contrast the NYHA III/IV patients decreased (23% and 11%) due to deaths, significantly more in the IMS group (treatment group comparison of NYHA I/II vs. III/IV vs. Death: p<0.036 for 6 and 12-months post-MI). Univariate correlates of a good outcome (not developing NYHA III/IV or Death) at 1-year post-MI were treatment assignment to ERV and NYHA I/II at baseline (p<0.046 for both).Only treatment assignment to ERV was significant in a multivariate model for good outcome at 1-year post-MI OR=0.31 ( 95%CI 0.13-0.76, p=0.01). Conclusion: Patients who initially survive cardiogenic shock have good long-term survival with high functional capacity. Patients assigned to ERV have a lower rate of deterioration in FC than IMS patients. A strategy of ERV is an independent strong predictor of 1year post-MI survival with good FC. ERV in the acute setting is a superior strategy with respect to 1-year post MI survival and FC.
Background: the value of late recanalization of the infarct vessel after myocardial infarction beyond the time window compatible with myocardial salvage remains debated Method: DECOPI is a randomized trial enrolling patients with angiographically-proven occlusion of the infarct vessel 2 to 15 days after onset, randomized to angioplasty or medical therapy. Left ventricular and coronary angiography were repeated at 6 months. Follow-up was clinical for 2 years. The primary endpoint was combined cardiovascular death, non fatal myocardial infarction and ventricular tachyarrythmias. Results: 212 patients were randomized. In the angioplasty arm, 80.4% of the patients had placement of a stent and 9.4% a GpIIb/IIIa blocker. TIMI 3 flow was reestablished in 82% of the patients at the end of the procedure. After a mean follow-up of 34 months, there was no difference in the primary endpoint between angioplasty and medical therapy (7.3 vs8.7%, NS). At 6 month angiography, the infarct artery was patent in 82.7% vs 32.7% in the angioplasty and medical groups respectively (p<0.0001). However, there was a 12% reocclusion and a 47% restenosis rate in the angioplasty arm and a 32% spontaneous recanalisation rate in the medical arm. Left ventricular ejection fraction was 3.5% higher in the angioplasty arm (p=0.025). When patients are categorized on the basis of patency at 6-month, independently of randomization, patients with a patent infarct artery have markedly improved outcomes: lower subsequent mortality 1% vs 9.1% (p=0.032), 6% higher left ventricular ejection fraction (p=0.004) and a trend towards a lower incidence of the primary endpoint (2% vs 6.1%, p=0.18) Conclusion: These results suggest that there is little clinical benefit to routine late recanalization of the infarct artery. However, recanalization is associated with improved ejection fraction. Patients with a patent vessel at 6-months appear to fare substantially better than patients with occlusion. This suggests that prevention of reocclusion and restenosis are key to the clinical benefit of late recanalization. Background: Concern remains as to whether benefit of primary percutaneous coronary intervention (pPCI) is not abolished by treatment delay in patients (pts) with acute myocardial infarction (AMI) who have to be transferred for pPCI to an invasive center from community hospitals. Methods: A prospective registry of consecutive unselected patients treated with pPCI within 12 hours of AMI in a single very high-volume tertiary center was interrogated. Before/during transport patients were pretreated with aspirin and usually heparin but not with fibrinolytics or glycoprotein receptor inhibitors. Long-term survival was established by telephone contact and through National Death Registry. Results: From 02/2001 through 01/2002 pPCI was performed in 602 pts including 457 pts transferred from community hospitals (transfer distance ranged 3-100 kilometers (kms), exceeded 30 kms in 40% pts). Transferred pts did not differ significantly from nontransferred patients with the exception of older age (61 vs. 54 years, p=0.02), longer time from onset of pain to admission to our center (3.2 vs. 2.2 hours, p=0.0005), and lower incidence of shock on admission (3% vs. 9%). The overall incidence of "not-low-risk" characteristics was the same (70%) Rates of stenting (75% transferred vs. 82% nontransferred) and abciximab use in cathlab (48% vs. 53%) were high and comparable in both groups. TIMI 3 flow was achieved in 83% and 85% pts after pPCI, respectively (NS).
One-year follow up was 100% complete. Mortality was similar in transferred and nontransferred pts (6% and 7%, respectively).
Conclusion:
Patients with AMI transferred from distant hospitals for up to 100 kms for non-facilitated primary coronary intervention have good one-year survival (similar to that of patients originally admitted to an invasive center) even though transport to an invasive center results in treatment delay.
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Background:
The presence of left bundle brunch block (LBBB) has been associated with poor outcomes in patients with myocardial infarction (MI). Whether this is true in the angioplasty era is not known. We sought to evaluate the outcome of patients with acute MI and LBBB on initial electrocardiogram (EKG) treated with primary angioplasty. Methods: We evaluated 1,483 patients who were randomized to primary angioplasty for the treatment of acute MI in the Primary Angioplasty in Myocardial Infarction (PAMI) trials and had information about the presence or absence of LBBB on presenting EKG. Patients with LBBB (n=39, 2.6%) on presenting EKG were compared to patients with ST segment elevation. Results: Patients with LBBB were older (69 vs 61 years, p<0.0001), had more frequent history of hypertension (62% vs 45%, p=0.038), prior coronary artery bypass surgery (10% vs 3.4%, p=0.048), they presented more often with Killip class >1 (20.5% vs 9.7%, p=0.050), and had more multivessel disease (64% vs 50%, p=0.013). There was no significant difference in initial or final TIMI (Thrombolysis in MI) flow, use of stent, left anterior descending infarct related artery, or ejection fraction. The incidence of in-hospital major adverse cardiac events (MACE) including death, ischemic target vessel revascularization (I-TVR) and reinfarction, tended to be higher in patients with LBBB (13% vs 5.5%, p=0.068) due primarily to significant increased in-hospital death (10% vs 3.1%, p=0.035).
In multivariate logistic regression analysis, LBBB was an independent predictor of in-hospital death after adjusting for other variables (odds ratio 4.04, 95% confidence interval 0.99-16.4, p=0.05).
Conclusions:
Patients with acute MI and LBBB on presenting EKG have increased MACE and mortality despite treatment with primary angioplasty. The presence of LBBB was an independent predictor of in-hospital death.
